

Journal of Visualized Experiments

Imaging Flow Cytometry to Evaluate Altered Endocytic CD1d Trafficking

--Manuscript Draft--

Article Type:	Methods Article - Author Produced Video
Manuscript Number:	JoVE57528R2
Full Title:	Imaging Flow Cytometry to Evaluate Altered Endocytic CD1d Trafficking
Keywords:	Imaging Flow Cytometry, ImageJ-Fiji, IDEAS, Transcriptomics, Pathway analysis, Cytoscape
Corresponding Author:	Shouxiong Huang University of Cincinnati College of Medicine Cincinnati, Ohio UNITED STATES
Corresponding Author's Institution:	University of Cincinnati College of Medicine
Corresponding Author E-Mail:	shouxiong.huang@uc.edu
First Author:	Shouxiong Huang
Other Authors:	Manju Sharma
	Xiang Zhang
Author Comments:	See our letter
Additional Information:	
Question	Response
If this article needs to be "in-press" by a certain date, please indicate the date below and explain in your cover letter.	

TITLE:

Imaging Flow Cytometry to Evaluate Altered Endocytic CD1d Trafficking

AUTHORS:

Manju Sharma, Xiang Zhang, Shouxiong Huang

Department of Environmental Health, University of Cincinnati College of Medicine, Cincinnati, OH

sharmamu@ucmail.uc.edu

xiang.zhang@uc.edu

Shouxiong.huang@uc.edu

Corresponding Authors:

Shouxiong Huang

Tel: (513)-558-7572

Xiang Zhang

KEYWORDS:

Imaging Flow Cytometry, ImageJ-Fiji, IDEAS, Transcriptomics, Pathway analysis, Cytoscape

SUMMARY:

Imaging flow cytometry provides an ideal approach to detect the morphological and functional alteration of cells at individual and populational levels. Disrupted endocytic function for lipid antigen presentation in pollutant-exposed human dendritic cells was demonstrated with a combined transcriptomic profiling of gene expression and morphological demonstration of protein trafficking.

ABSTRACT:

Populational analyses of the morphological and functional alteration of endocytic proteins are challenging due to the demand of image capture at a single cell level and statistical image analysis at a populational level. To overcome this difficulty, we used imaging flow cytometry and transcriptomic profiling to determine altered subcellular localization of the cluster of differentiation 1d protein (CD1d) associated with impaired endocytic gene expression in human dendritic cells (DCs), which were exposed to the common lipophilic air pollutant benzo[a]pyrene. The colocalization of CD1d and endocytic marker Lamp1 proteins from thousands of cell images captured with imaging flow cytometry was analyzed using IDEAS and ImageJ-Fiji programs. Numerous cellular images with co-stained CD1d and Lamp1 proteins were visualized after gating on CD1d⁺Lamp1⁺ DCs using IDEAS. The enhanced CD1d and Lamp1 colocalization upon BaP exposure was further demonstrated using thresholded scatterplots, tested with Mander's coefficients for co-localized intensity, and plotted based on the percentage of co-localized areas using ImageJ-Fiji. Our data provide an advantageous instrumental and bioinformatic approach to measure protein colocalization at both single and

45 populational cellular levels, supporting an impaired functional outcome of transcriptomic
46 alteration in pollutant-exposed human DCs.

47 48 **INTRODUCTION:**

49 Antigen presentation typically involves intracellular protein trafficking, which has been often
50 investigated using morphological characterization and phenotypic profiling of antigen
51 presenting cells¹⁻³. To integrate the advantages of imaging and phenotyping methods, we
52 describe an imaging analysis platform at both single cell and population levels to demonstrate
53 an altered protein colocalization in human dendritic cells (DCs). In peptide antigen
54 presentation, major histocompatibility complex (MHC) class I molecules bind a short peptide (8-
55 10 residues) in the endoplasmic reticulum to activate conventional CD8⁺ T cells, while MHC
56 class II molecules bind a relatively longer peptide (~20 residues) in endocytic compartments to
57 activate conventional CD4⁺ T cells^{1,4}. In contrast, lipid-specific T cells are activated by CD1
58 proteins with lipid antigens loaded mainly in endocytic compartments^{5,6}. Lipid antigen
59 presentation requires the supply of lipid metabolites produced in lipid metabolism⁷⁻¹⁰ and the
60 loading of functional lipid metabolites to CD1 proteins in endocytic compartments^{5,6}. In this
61 context, various cellular factors modulating lipid antigen presentation, especially in
62 environmental exposure of lipophilic pollutants and immune disorders, are critical to be
63 defined. In this study, we used transcriptomic analysis, image profiling, and cellular and
64 populational imaging analysis of human monocyte-derived DCs to determine the endocytic
65 protein trafficking contributing to lipid antigen presentation in pollutant exposure. Certainly,
66 this combined platform can be applied to studying subcellular protein trafficking and
67 colocalization in different biological processes.

68
69 Technically, subcellular protein localization was usually demonstrated using confocal
70 microscopy and statistically analyzed in a limited number of detected cells^{1-3,11}. Moreover, flow
71 cytometry has been broadly applied to gate cell populations with co-stained signals of multiple
72 proteins at a cellular level¹²; however, this lacks a detailed visualization of subcellular protein
73 colocalization. To achieve comprehensive and statistical analyses of percentage protein
74 colocalization at both cellular and population levels, we incorporate imaging profiling and
75 analysis approaches to determine the features of protein colocalization with biological
76 relevance. Specifically, we use imaging flow cytometry to detect the colocalization of CD1d and
77 lysosomal-associated membrane protein 1 (Lamp1) proteins in this study. Quantitative analysis
78 of colocalized molecules was previously difficult to be performed at a populational scale. In this
79 study, we adapted the ImageJ-Fiji program to examine the percentage of protein colocalization
80 with a large number of co-stained cells at both populational and individual cellular levels.
81 Specifically, we measured co-localized areas, intensity, and populational size to support the
82 conclusion that the CD1d protein was largely retained in late endocytic compartments of
83 human DCs in exposure to a lipophilic pollutant benzo[a]pyrene (BaP)¹³. This combined cellular
84 and population imaging analysis provided highly reproducible, comprehensive, and statistically
85 significant results of CD1d-Lamp1 colocalization relevant to inhibited lipid antigen presentation.

86
87 The transcriptome of BaP-exposed human DCs strongly supported the hypothesis that
88 endocytic lipid metabolism and CD1d endocytic trafficking were impaired in BaP exposure. To

test this hypothesis, we applied imaging flow cytometry to profile the images of DC population that were co-stained with multiple proteins including CD1d, endocytic markers, and DC markers. Finally, co-stained cells were statistically analyzed to demonstrate the percentage of intensity and areas of CD1d and Lamp1 colocalization.

PROTOCOL:

Human protocols in this study were approved by the Institutional Review Board of the University of Cincinnati and all methods were performed in accordance with the relevant guidelines and regulations. Blood samples from healthy donors were obtained from the Hoxworth Blood Center at the University of Cincinnati Medical Center.

1. Transcriptomic Profiling of Pollutant-Exposed Human Monocyte-Derived DCs

1.1. Total RNA extraction of BaP-exposed DCs

1.1.1. Differentiate human DCs using cytokines GM-CSF and IL-4, and expose DCs to BaP for 4 days¹³.

1.1.2. Sort BaP-exposed DCs using flow cytometry based on the surface expressed markers (Lineage⁻HLA-DR⁺), the majority of which consists of conventional DCs (CD11c⁺CD1c⁺)¹³. Typically, sort 10,000 DCs into culture medium containing 10% FBS, centrifuge DCs at 600 x g and 4 °C for 6 min, and immediately remove the supernatant by aspiration using a 1 mL pipette tip.

1.1.3. Once the supernatant is removed by aspiration, lyse the cell pellet by adding 0.4 mL of Lysis/Binding Buffer from the RNA isolation kit for storage in -80 °C before RNA extraction.

1.1.4. Use the RNA isolation kit with the total RNA extraction protocol to extract the total RNA¹⁴. Measure the RNA integrity using a Bioanalyzer¹⁵.

1.2. Transcriptomic analysis of sorted DCs (Figure 1A)

1.2.1. Prepare the library for RNA-seq using a RNA Library preparation kit. In short, fragment the isolated poly-A RNA (~200 bp), reverse transcribe the fragments to the 1st strand of the cDNA, and follow by the second strand cDNA synthesis labeled with dUTP.

1.2.2. Ligate double strand cDNA to the adapter with a stem-loop structure after bead purification, end-repairing and dA-tailing. Excise the uracil residues in the 2nd strand of the cDNA and adapter loop with USER (Uracil-Specific Excision Reagent) enzyme to maintain strand specificity and open the adapter loop for PCR.

1.2.2.1. Perform 13 cycles of PCR using universal and index-specific primers to enrich the indexed library. Clean up the library and run on a Bioanalyzer DNA High Sensitivity chip to check the library quality and size distribution.

1.2.3. Use a library quantification kit and a real-time PCR system combined with library size information to calculate library concentration *via* a standard curve method.

1.2.4. Proportionally pool individually indexed compatible libraries and adjust the final total concentration to 15 pM. Perform library cluster generation and sequence the library at a setting of single read 1x50 bp to generate ~25 million reads per sample.

1.3. Sequencing

1.3.1. Load the sequencing and indexing reagents to the SBS and PE reagent racks, respectively. Place the reagents in a laboratory-grade water bath for 1 h until all the ice has melted and the reagents in each bottle/tube are mixed properly.

1.3.2. Prepare the ICB mix by adding the thawed dye and -20 °C enzyme to the bottle and mix. Prepare a NaOH solution according to the sequencing instructions. Place all reagents at 4 °C until ready to use.

1.3.3. During the 1 h waiting period, power on the sequencer. Wait for the DONOTEJECT drive to appear and connect the computer to a network drive.

1.3.4. Launch the sequencer control software.

1.3.5. Prepare 2 L of Maintenance Wash solution that contains 0.5% Tween 20 and 0.03% ProClin 300 in laboratory-grade water.

1.3.6. In the SBS reagent rack, add ~100 mL of Maintenance Wash solution to each of the 8 bottles, and screw funnel caps to the bottles. In the PE reagent rack, add ~12 mL of Maintenance Wash solution to each of the ten 15 mL conical tubes, and discard the caps.

1.3.7. Load the two racks with the solution filled bottles/tubes to the sequencer.

1.3.8. From the sequencer control software, choose the Maintenance Wash; follow the instructions on screen to clean the sequencer fluid system until the process is completed.

1.3.9. Start a New Run in the **SEQUENCE** tab from the software; direct the output data to a network drive. Choose parameters for single read 1x50 bp with single index multiplexed libraries.

1.3.10. Optionally, log into the BaseSpace Sequence Hub so that the sequencing status can be remotely monitored via a computer or smart phone.

1.3.11. Upload a Sample Sheet for demultiplexing and provide reagent information according to the software requirement.

1.3.12. Load SBS and PE reagents to the sequencer. Prime the system with a used flow cell (~15 min).

1.3.13. Once the cluster generation is completed (~4.5 h), take the flow cell out, lightly spray the flow cell with water, and wipe it dry using lens paper. Lightly spray the flow cell with 95% ethanol and wipe it dry. Check against a light to make sure that the surface is clean without debris or salt residue.

1.3.14. After the Prime step is completed, load the clustered flow cell and start the sequencing. The Sequence Analysis Viewer software will automatically be started.

1.3.15. Monitor the sequencing data quality via SAV including cluster density, reads pass filter, cluster pass filter %, % ≥Q30, Legacy phase/prophase %, indexing QC, *etc.* This helps to understand the data quality and troubleshoot.

1.3.16. Change the flow cell gasket and perform a Maintenance Wash after the sequencing is completed. The sequencer is ready for the next run.

1.4. Bioinformatic analysis

1.4.1. Perform bioinformatics RNA-seq data analysis¹³.

2. Pathway Analysis of Transcriptomic Profiles (Figure 1B)

2.1. Use an edgeR Bioconductor to compare resultant gene expression intensity counts between BaP-exposed and non-exposed DCs from three donors. Then, identify differentially expressed genes between BaP-exposed and non-exposed DCs based on the absolute fold change (>2 folds) and the false discovery rates (FDRs)-adjusted *p*-values (<0.05).

2.2. To predict the functional clusters of differentially expressed genes, use the ToppCluster software package to search the altered genes against several databases including KEGG and REACTOME and generate clustering data. ToppCluster uses the hypergeometric test to obtain functional enrichment achieved via the gene list enrichment analysis¹⁶.

2.3. Further input the results from these function clusters to Cytoscape^{17,18} Version 3.3.0, a broadly used open source software platform for visualizing complex networks. Thus, the genes involved in different clusters or pathways, including endocytic clusters and lipid metabolism, are shown in a network with color annotation of the averaged fold change of gene expression (Figure 1B)¹³.

3. Imaging Flow Cytometry of CD1d and Lamp1 Colocalization

3.1. Antibody labeling of BaP-exposed DCs

3.1.1. Expose 0.5×10^6 human DCs to $5.94 \mu\text{M}$ BaP for 4 days at 37°C in 2 mL of complete Dulbecco's Modified Eagle's Medium. Harvest DCs by centrifugation at $400 \times g$ for 10 min. Block the differentiated DCs by incubating cells with human serum blocker and anti-human Fc receptor antibodies for 10 min in ice, including anti-human CD16, CD32, and CD64 antibodies.

3.1.2. Incubate Brilliant Violet 421-anti-CD1c (L161), phycoerythrin/cyanine dye 7 (PE/Cy7)-anti-HLA-DR, and PE/Cy5-anti-CD11c with DCs for 20 min in ice. **Table 1** shows this list of antibodies.

3.1.3. Fix DCs with 4% paraformaldehyde in PBS and permeabilize them with Permeabilization Wash Buffer. Perform the intracellular staining with a mixture of PE-labeled purified anti-human CD1d (51.1) and the Alexa Fluor 647-labeled anti-Lamp1 (CD107a) (H4A3).

3.2. Imaging flow cytometry measurement (**Figure 2**)

3.2.1. Analyze the stained samples using an imaging flow cytometer at the flow cytometry core of Cincinnati Children's Hospital using a 40X objective to yield 300 pixels for a cell with around $10 \mu\text{m}$ in diameter. One-pixel size is approximately $0.5 \mu\text{m}$ by $0.5 \mu\text{m}$ of the object.

3.2.3. Acquire 10,000 cellular images in an unbiased manner according to the manufacturer's instruction.

4. Imaging Analyses of Flow Cytometry Images

4.1. Colocalization analysis using IDEAS software (**Figure 2**)

4.1.1. Perform compensation with single-stained versus non-stained samples by setting the fluorescence intensity of non-stained samples below the threshold, including non-stained BaP-exposed DCs with BaP autofluorescence, *e.g.*, **Analyze | Colocalization | Colocalization**.

4.1.2. Gate stained cells to obtain the subsets of HLA-DR⁺CD11c⁺CD1d⁺Lamp1⁺ cells (**Figure 2A**) and show cellular images in the gated subsets (**Figure 2B**).

4.1.3. Save cell images in a png format based on two technical inclusion criteria, the visual presence of strong co-stained signals and subcellular localization of CD1d and Lamp1 proteins, for the colocalization analyses using ImageJ-Fiji (**Figure 2B**).

4.2. Use software ImageJ-Fiji to perform colocalization analysis (**Figure 3**).

4.2.1. Prepare the input image files by merging the 100 saved cell images for non-exposed and BaP-exposed human DCs, respectively (**Figure 3A**).

4.2.2. Analyze CD1d (Red) and Lamp1 (Green) colocalization using a scatterplot.

4.2.2.1 Run ImageJ-Fiji program. Open the .png file with 100 cell images (**Figure 3B** and **Figure 4A**): **File | Open**.

4.2.2.2 Split the image with merged red and green channels into two images with either a red or a green channel: **Image | Color | Split channels**.

4.2.2.3 Draw a scatterplot using the commands **Analyze | Colocalization | Colocalization Threshold**. Save the scatterplot using the **PrintScreen** key.

4.2.3. Calculate Mander's colocalization coefficients for each single cellular image (n=100) (**Figure 4B**)

4.2.3.1 Select a single cell image on the image file with split channels using the **Oval** selection tool.

4.2.3.2 Use the commands **Analyze | Colocalization | Colocalization Threshold**. Select **Channel 1** from the dialogue box of region of interest (ROI). Keep all calculation options including **Mander's using thresholds** for each cell image.

4.2.3.3 Repeat this calculation for all 100 cell images.

4.2.3.4 Save and open the results using a spreadsheet.

4.2.3.5 Plot the average and standard errors for "thresholded Mander's coefficients" (n=100, 0 means no colocalization and 1 means perfect colocalization). Use Student's t-test to calculate the *p* value for the comparison between BaP-exposed and non-exposed groups (**Figure 4B**).

4.2.4. Calculate the percent of thresholded pixel intensity co-localized between CD1d and Lamp1 for multiple cell images (n=100) (**Figure 5C**).

4.2.4.1. Use the same analysis protocol in 4.2.3 and additionally select the result option **% intensity above threshold colocalized**.

4.2.4.2. Perform this analysis together with Mander's colocalization coefficients.

4.2.4.3. Similarly plot the average and standard errors for % intensity colocalized between CD1d and Lamp1. Use Student's t-test to calculate the *p* value for comparison between BaP-exposed and non-exposed groups (**Figure 5C**).

REPRESENTATIVE RESULTS:

The lipophilic pollutant BaP alters endocytic gene clusters in human DCs. Human monocyte-derived DCs from each donor (n=3) were incubated with BaP and sorted for labeled conventional DCs, which were further used for RNA extraction and transcriptomic analysis as described. Upon the normalization of gene expression, altered genes between BaP-exposed and non-exposed groups were clustered according to the functional correlation of differentially expressed genes. We input the altered gene list to the Toppcluster program¹⁶ for the analyses of relevant cellular pathways and perform the statistical test using a false discovery rate (FDR) correction of *p* values (**Figure 1B**). Several major altered gene clusters, including lipid metabolism and endocytic functions, were identified in BaP-exposed DCs. In this study, we specifically focused on the functional test of endocytic trafficking, because CD1-mediated antigen presentation has been highly dependent on the lipid antigen loading in the endocytic pathway^{5,19-21}.

CD1d endocytic trafficking is demonstrated using imaging flow cytometry. Upon obtaining a large number of cell images using imaging flow cytometry, we started using the IDEAS program to visualize individual cellular images through conveniently gating cell populations co-stained with multiple antibodies (**Figure 2A**). Specifically, we were able to gate the major DC population co-stained with HLA-DR and CD11c to further show the DCs with CD1d and Lamp1 co-expression (**Figure 2A**). Co-stained signals can be enriched through gating the cell population with double stain of CD1d and Lamp1 (**Figure 2A**). We first showed the non-exposed normal DCs with minimal colocalization of CD1d and Lamp1 proteins, indicating the basal level of CD1d endocytic trafficking and high level of surface expression at physiological conditions (**Figure 2B**)^{5,19-21}. To measure the colocalization of CD1d and Lamp1 proteins, we initially used IDEAS to show a slight increase of bright detail similarity between CD1d and Lamp1 proteins with BaP exposure¹³. The bright detail similarity was calculated based on the Pearson's correlation coefficient for testing the correlation of two factors, while CD1d and Lamp1 proteins were unlikely highly overlapped in physiological condition, indicating that CD1d is able to transiently traffic through late endocytic compartments to obtain functional lipid antigens. Thus, it is more biologically meaningful to test whether the CD1d protein in BaP exposure retains more in the late endocytic compartments as reflected by the increased percentage of overlapped CD1d and Lamp1 proteins using the imaging analysis software Fiji in the ImageJ package. Finally, retention of the CD1d protein in late endocytic compartments can be used to functionally confirm altered endocytic gene profiles in BaP exposure.

Co-localized intensity and area between CD1d and Lamp1 proteins was measured. To obtain a reproducible threshold setting and percentages of co-localized areas and intensity, we applied ImageJ-Fiji²², which has also been used in several other studies²³⁻²⁵. We randomly select CD1d⁺Lamp1⁺ cells with strong co-stain and clear subcellular localization of CD1d and Lamp1 proteins as input images (**Figure 2B**). Individual cellular images can be merged to a single image file for one consistent analysis (**Figure 3A**). In our study, we merged 100 cell images and opened it in the program to analyze by setting "colocalisation thresholds" (**Figure 3B**). The colocalization of pixel intensity between two channels (PE-labeled CD1d and AF647-labeled Lamp1) was shown overall with a scatterplot by detecting the co-localized pixels from these 100

cell images (**Figure 4A**). In this plot, horizontal and vertical lines represent Costes's thresholds and the diagonal lines represent the ratio of overall pixel intensity between two channels. The Costes's threshold provides a visible setting for removing weak pixels from two overlapped channels. The resulted scatterplot shows an increased colocalization of CD1d and Lamp1 proteins in BaP exposure. Moreover, we quantified the degree of co-localized areas between CD1d and Lamp1 proteins using Mander's coefficients (**Figure 4B**). Consequently, Mander's coefficients demonstrate increased colocalized areas between CD1d and Lamp1 in late endocytic compartments of BaP-exposed DCs comparing with non-exposed DCs, as statistically supported by Student's t-tests (**Figure 4B**). However, if protein intensity is heterogeneous between colocalized and non-colocalized areas, colocalized intensity will be unparalleled to colocalized areas. Therefore, it is also necessary to further exam the colocalization based on intensity (**Figure 4C**). As a result, each column represents an averaged calculation of percentage of colocalized intensity from multiple cell images (n=100) between BaP-exposed and non-exposed conditions for a pair of co-localized proteins. Student's t-tests also show statistical significance (n=100, $p<0.001$) between BaP-exposed and non-exposed groups (*) with indicated standard errors. Altogether, our data demonstrate that the CD1d protein was retained in late endosomes at BaP exposure, supporting that BaP-altered gene expression further contribute to the impaired endocytic function and CD1d trafficking.

In summary, CD1d-Lamp1 colocalization enhances upon BaP exposure. Multiple parameters based on cell images (**Figure 2B**), including scatterplots with overlapped pixel intensity (**Figure 4A**), enhanced Mander's coefficients (**Figure 4B**), and increased percentage of overlapped intensity (**Figure 4C**), support CD1d endocytic retention at BaP exposure. This colocalization analysis of cellular images is a similar and accurate approach to determine the degree of protein colocalization and demonstrate biological mechanisms of cell functions, for example, endocytic function consistent with disrupted endocytic gene expression, further contributing to the inhibited activation of CD1d-restricted T cells¹³.

Figure 1: Perturbation of DC transcriptomes in BaP exposure (A) Flowchart of RNA-Seq. First, quality control (QC) analysis was performed to examine the quality of total RNA. Using an automated system and high-quality total RNA as input, poly-A RNA was isolated, which demonstrated depleted rRNA in poly-A RNA QC analysis. The poly-A RNA was then subjected to automated library preparation and indexing via PCR. Next, the amplified library was analyzed by a Bioanalyzer for QC with expected yield and size distribution. After qPCR quantification, indexed libraries were pooled and clustered onto flow cell for sequencing, and the sequencing data quality was real-time monitored. The axis represents relative counts of flow cytometry staining signals. **(B)** Altered genes were grouped in different functional clusters and the gene clusters associated with endocytic function and lipid metabolism are shown. Red: CD1d; Green: Lamp1.

Figure 2: Analysis of cellular images using the IDEAS program and calculation of bright detail similarity. (A) Monocyte-derived DCs from healthy donors were firstly gated on HLA-DR+CD11c+ cells and further gated on CD1d⁺Lamp1⁺ cells using the IDEAS program. (B) Cellular

images were extracted from the HLA-DR⁺CD11c⁺CD1d⁺Lamp1⁺ population for cellular image visualization.

Figure 3. Analysis of cellular images using the Fiji-ImageJ program. Cells with strong co-stain of CD1d and Lamp1 proteins were randomly selected for the image analysis using Fiji-ImageJ, but cells* with invisible or weak staining for either CD1d or Lamp1 protein was excluded as in **Figure 2B**. **(A)** These randomly selected cellular images were assembled into a single image file as an input image. **(B)** The colocalization analysis was performed through setting the colocalization thresholds for both green and red channels. The scatterplots were generated with threshold calculation.

Figure 4. Colocalization of CD1d and Lamp 1 proteins. Use similar dataset reported in Sharma *et al.*¹³, co-localized pixel intensity between CD1d and Lamp1 proteins from DCs at BaP-exposed and non-exposed conditions was recalculated and shown with scatterplots **(A)**. Mander's coefficients for CD1d and Lamp1 colocalization were calculated and are shown with an average from selected cell images **(B)**. The percentage of co-localized pixel intensity was also calculated **(C)**. Statistical significance (n=100, $p<0.001$) was obtained with Student's t-tests in comparison to the non-exposed group (**). Standard errors were indicated. Data are from one assay with cells from a healthy donor. Two independent assays were performed with similar results.

Table 1. Antibodies used in this study.

Due to shared excitation and emission wavelengths, fluorophores PE/Cy5 and AF647 partially overlapped at staining signals. We use these fluorophores to label a surface protein (CD11c) and an intracellular protein (Lamp1) respectively to avoid their signal overlapping at a subcellular level. We also use optimal titration and compensation to minimize the overlapped signals between both fluorophores.

DISCUSSION:

Functional confirmation of an altered gene pathway is challenging, because of widely impacted gene expression involving multiple pathways and the difficulty to functionally integrate individual and populational cellular activities. We employed imaging flow cytometry to specifically test the functional impact on CD1d trafficking in endocytic compartments. Imaging flow cytometry integrates the populational measurement of cells and the individual demonstration of subcellular colocalization of multiple proteins. Confocal microscopy has previously provided high resolution in measuring protein colocalization, and flow cytometry is able to provide comprehensive phenotyping for different cell populations. Imaging flow cytometry combines the advantages of confocal microscopy and flow cytometry at acceptable image resolution to analyze protein colocalization in a high-profile manner for functional confirmation of transcriptomic alteration by environmental pollutants.

Analyses of colocalization of multiple proteins in a populational scale are technically demanding, because (i) detailed analyses of multiple individual cells are labor-intensive and relatively biased; (ii) it is difficult to define an optimal threshold for interpreting overlapped pixels based on the intensity or area of positive staining; and (iii) balanced observation of

individual and populational cells is critical. In this study, we focused on performing a biologically meaningful observation, a statistical significance test, and an imaging demonstration of co-localized proteins. To achieve this goal, we first obtained thousands of images of human DCs using imaging flow cytometry. Quantitative analyses of imaging files combined a bright detail similarity analysis using the software IDEAS and a statistically tested colocalization analysis using Fiji-ImageJ. The IDEAS program allows gating the co-stained population, calculating colocalization of two proteins using Pearson's correlation coefficient-based bright detail similarity, and randomly selecting co-stained cells with subcellular localization of proteins¹³. To further achieve the biological relevant demonstration of co-localized proteins, we used ImageJ-Fiji software and applied the Mander's coefficient to calculate the percentage of co-localized areas and overlapped pixel intensity to demonstrate the degree of CD1d localization in the endocytic pathway.

The critical step for using the ImageJ-Fiji program is to perform single cell imaging analysis. Variation of percentage protein colocalization from individual cells can be monitored in comparison to visually merged colors from single cell images. By averaging the percentage protein colocalization from all 100 cells, the means and standard errors can be calculated to demonstrate protein colocalization and functional correlation at a populational level. This bioinformatics analysis is simple and straightforward without concerning ambiguous results, because this analysis offers a reproducible threshold calculation using the Costes's method to produce the same resulted thresholds for the same data sets and similar thresholds for similar datasets²⁶. The limitation of this technique is the labor-intensive manual input of single cell images and potentially subjective selection of visually co-stained cells using the IDEAs software. In our study, we analyze 100 cell images from each group and we set reproducible selection criteria, including strong co-stained signals and clear subcellular localization of CD1d and Lamp1 proteins. Overcoming these limitations requires technical improvement of analytical software to allow batch analysis and objective selection of single cells based on morphological features beyond the staining intensity provided by flow cytometry. In summary, combined cellular and population imaging analysis will provide highly reproducible, comprehensive, statistically tested, and biologically relevant results of percentage protein colocalization. We believe this CD1d-Lamp1 colocalization analysis can serve as a successful example of high profile cellular imaging analyses to answer broader questions on functional and morphological alteration of cellular proteins.

DISCLOSURES:

The authors have nothing to disclose

ACKNOWLEDGEMENTS:

The authors thank Robert Giulitto (Hoxworth blood center) for human blood samples and Dr. Liang Niu for the normalization of gene expression reads. We also thank grant support from the National Institute of Environmental Health Sciences (ES006096), Center for Environmental Genetics (CEG) pilot project (S.H.), National Institute of Allergy and Infectious Diseases (AI115358) (S.H.), University of Cincinnati University Research Council award (S.H.), and University of Cincinnati College of Medicine Core Enhancement Funding (X. Z.).

REFERENCE

- 1 Roche, P.A., Cresswell, P. Antigen Processing and Presentation Mechanisms in Myeloid Cells. *Microbiology Spectrum* **4** (3) (2016).
- 2 Huang, S. *et al.* MR1 uses an endocytic pathway to activate mucosal-associated invariant T cells. *The Journal of experimental medicine* **205** (5), 1201-1211 (2008).
- 3 Nakamura, N. *et al.* Endosomes are specialized platforms for bacterial sensing and NOD2 signalling. *Nature* **509** (7499), 240-244 (2014).
- 4 Blum, J.S., Wearsch, P.A., Cresswell, P. Pathways of antigen processing. *Annual review of immunology* **31**, 443-473 (2013).
- 5 Brennan, P.J., Brigl, M., Brenner, M.B. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. *Nature reviews. Immunology* **13** (2), 101-117 (2013).
- 6 Zajonc, D.M., Kronenberg, M. CD1 mediated T cell recognition of glycolipids. *Current opinion in structural biology* **17** (5), 521-529 (2007).
- 7 Cox, D. *et al.* Determination of cellular lipids bound to human CD1d molecules. *PloS one* **4** (5), e5325 (2009).
- 8 Yuan, W., Kang, S.J., Evans, J.E., Cresswell, P. Natural lipid ligands associated with human CD1d targeted to different subcellular compartments. *Journal of immunology* **182** (8), 4784-4791 (2009).
- 9 Huang, S. *et al.* Discovery of deoxyceramides and diacylglycerols as CD1b scaffold lipids among diverse groove-blocking lipids of the human CD1 system. *Proceedings of the National Academy of Sciences of the United States of America* **108** (48), 19335-19340 (2011).
- 10 de Jong, A. *et al.* CD1a-autoreactive T cells recognize natural skin oils that function as headless antigens. *Nature immunology* **15** (2), 177-185 (2014).
- 11 Trombetta, E.S., Mellman, I. Cell biology of antigen processing *in vitro* and *in vivo*. *Annual review of immunology* **23**, 975-1028 (2005).
- 12 Maecker, H.T., McCoy, J.P., Nussenblatt, R. Standardizing immunophenotyping for the Human Immunology Project. *Nature reviews immunology* **12** (3), 191-200 (2012).
- 13 Sharma, M. *et al.* Inhibition of endocytic lipid antigen presentation by common lipophilic environmental pollutants. *Science Reports* **7** (1), 2085 (2017).
- 14 Boom, R. *et al.* Rapid and simple method for purification of nucleic acids. *Journal of clinical microbiology* **28** (3), 495-503 (1990).
- 15 Nachamkin, I. *et al.* Agilent 2100 bioanalyzer for restriction fragment length polymorphism analysis of the *Campylobacter jejuni* flagellin gene. *Journal of clinical microbiology* **39** (2), 754-757 (2001).
- 16 Kaimal, V., Bardes, E.E., Tabar, S.C., Jegga, A.G., Aronow, B.J. ToppCluster: a multiple gene list feature analyzer for comparative enrichment clustering and network-based dissection of biological systems. *Nucleic acids research* **38** (Web Server issue), W96-102 (2010).
- 17 Bauer-Mehren, A. Integration of genomic information with biological networks using Cytoscape. *Methods in molecular biology* **1021**, 37-61 (2013).
- 18 Cline, M.S. *et al.* Integration of biological networks and gene expression data using Cytoscape. *Nature protocols* **2** (10), 2366-2382 (2007).

524 19 Huang, S., Moody, D.B. Donor-unrestricted T cells in the human CD1 system.
 525 *Immunogenetics* **68** (8), 577-596 (2016).
 526 20 Huang, S. Targeting Innate-Like T Cells in Tuberculosis. *Frontiers in immunology* **7**, 594
 527 (2016).
 528 21 Moody, D.B., Porcelli, S.A. Intracellular pathways of CD1 antigen presentation. *Nature*
 529 *reviews. Immunology* **3** (1), 11-22 (2003).
 530 22 Schindelin, J. *et al.* Fiji: an open-source platform for biological-image analysis. *Nature*
 531 *methods* **9** (7), 676-682 (2012).
 532 23 Diard, M. *et al.* Stabilization of cooperative virulence by the expression of an avirulent
 533 phenotype. *Nature* **494** (7437), 353-356 (2013).
 534 24 Bader, E. *et al.* Identification of proliferative and mature beta-cells in the islets of
 535 Langerhans. *Nature* **535** (7612), 430-434 (2016).
 536 25 Eliceiri, K.W. *et al.* Biological imaging software tools. *Nature methods* **9** (7), 697-710
 537 (2012).
 538 26 Costes, S.V. *et al.* Automatic and quantitative measurement of protein-protein
 539 colocalization in live cells. *Biophysical journal* **86** (6), 3993-4003 (2004).







Figure2





B



Colocalisation Thresholds

Channel 1

Channel 2

Use ROI

Channel Combination

☒ Show Colocalized Pixel Map


☒ Use constant intensity for colocalized pixels

☒ Show Scatter plot



☒ Include zero-zero pixels in threshold calculation

☐ Set options

See: <http://uhnresearch.ca/wcif/imagej>



A Colocalization of CD1d and Lamp1



B n=100 *

C n=100 *

n=100 *

Antibodies	Fluorophores or secondary antibody
HLA-DR	Phycoerythrin/Cyanine 7 (PE/Cy7)
CD11c	Phycoerythrin/Cyanine 5 (PE/Cy5)
CD1c	Brilliant violet 421
Purified anti-human CD1d	PE-anti-mouse IgG2b
Lamp1	Alexa Fluor 647 (AF647)

Clone	
L243	
	3.9
L161	
	51.1
CD107a(H4A3)	

Name of Material/ Equipment	Company
Transcriptomics	Illumina
ImagingStream X	Millipore
mirVana miRNA Isolation Kit	Thermo Fisher
Agilent RNA 6000 Pico Kit	Agilent
Veriti 96-Well Fast Thermal Cyclers	Thermo Fisher
NEBNext Poly(A) mRNA Magnetic Isolation	New England Biolabs
Automated SMARTer Apollo system	Takara
NEBNext Ultra RNA Library Prep Kit for Illumina	New England Biolabs
Agencourt AMPure XP magnetic beads	Beckman Coulter
2100 Bioanalyzer	Agilent
Agilent High Sensitivity DNA Kit	Agilent
QuantStudio 5 Real-Time PCR System (Applied Biosystems)	Thermo Fisher
NEBNext Library Quant Kit	New England Biolabs
cBot	Illumina
TruSeq SR Cluster Kit v3 - cBot – HS	Illumina
HiSeq 1000	Illumina
TruSeq SBS Kit v3 - HS (50-cycles)	Illumina
Phycoerythrin/Cyanine 7 (PE/Cy7)	Bio Legend
Phycoerythrin/Cyanine 5 (PE/Cy5)	Bio Legend
Brilliant violet 421	Bio Legend
PE-anti-mouse IgG2b	Bio Legend
Alexa Fluor 647 (AF647)	Bio Legend

Catalog Number	Comments/Description
HiSeq 2500 v4	Illumina HiSeq system
100220	Imaging flow cytometry
	Total RNA extraction
	Total RNA QC analysis
	PCR, enzyme reaction
	PolyA RNA purification
	PolyA RNA purification
	Library preparation
	DNA purification
	Library QC, size distribution analysis
	Library QC, size distribution analysis
	Library quantification
	Library quantification
	Library cluster generation
	Library cluster generation
	Sequencing
	Sequencing
L243	
	3.9
L161	
	51.1
CD107a(H4A3)	



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Author(s):

Item 1 (check one box): The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via: ☒ Standard Access ☐ Open Access

Item 2 (check one box):

- ☒ The Author is NOT a United States government employee.
- ☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.
- ☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: “**Agreement**” means this Article and Video License Agreement; “**Article**” means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; “**Author**” means the author who is a signatory to this Agreement; “**Collective Work**” means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; “**CRC License**” means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; “**Derivative Work**” means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; “**Institution**” means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; “**JoVE**” means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; “**Materials**” means the Article and / or the Video; “**Parties**” means the Author and JoVE; “**Video**” means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the “Open Access” box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. Retention of Rights in Article. Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. Grant of Rights in Video – Standard Access. This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. Grant of Rights in Video – Open Access. This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. Government Employees. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. Likeness, Privacy, Personality. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. JoVE Discretion. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have

ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's


expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

CORRESPONDING AUTHOR:

Name:	Shouxiong Huang	
Department:	Department of Environmental Health	
Institution:	University of Cincinnati College of Medicine	
Article Title:	Imaging flow cytometry to evaluate altered endocytic CD1d trafficking	
Signature:		Date: Mar 06, 2018

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email submissions@jove.com or call +1.617.945.9051



Department of Environmental Health
University of Cincinnati College of Medicine
Kettering Laboratory Complex
160 Panzeca Way
Cincinnati, OH 45267-0056

Mar 06, 2018

Dear Editors:

We have revised the manuscript according to editorial comments. In particular, we have newly generated Fig. 1B to comprehensively show the sequenced gene network and generated Fig. 4 using different sets of 100 cell images to avoid the adaptation of previously published results. We have also revised the text to avoid repeating our published description.

Point-by-point responses to editorial comments are listed below.

Sincerely
Shouxiong Huang
Xiang Zhang

Editorial comments:

1. There is previously published text in the manuscript that must be revised before the manuscript can be accepted. Please see the attached iThenticate report and revise the following lines: 58-60, 130-134, 137-144, 152-168, 205-219, 223-228, 230-247, 300-314, 318-321

--modified.

2. There is discrepancy between the signed Author License Agreement and the access type selected in Editorial Manager. You have selected open access in the signed ALA but standard access in Editorial Manager. What access type do you want? Please sign and select the appropriate box in the attached ALA as well.

--corrected. We prefer standard access. We will take video using computers, because contents to be recorded are computational analyses.

3. Additional revisions are required for the written manuscript. Please see the comments in the attached manuscript.

--The manuscript was also revised according to detailed comments.

4. Please revise the protocol to be completely in the imperative tense. Furthermore, we need more details for protocol replication. These details cannot be referenced out and are needed if a particular step is to be filmed. The script is directly derived from the written protocol text.



--modified.

5. Please expand the Materials Table to include all materials and equipment (kits) used. We need as much information as possible. Please remove the commercial language (and branded products) from the written manuscript as well: AMPure XP, NEBNext, QuantStudio, Illumina, cBot, TruSeq, etc.

--removed.

6. Please ensure that the references appear as the following: [Lastname, F.I., LastName, F.I., LastName, F.I. Article Title. Source. Volume (Issue), FirstPage – LastPage (YEAR).] For more than 6 authors, list only the first author then et al. Please do not abbreviate journal titles.

--modified.